Shuttle Pharmaceuticals Stock Performance
SHPH Stock | USD 0.39 0.03 7.14% |
The entity has a beta of 0.82, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Shuttle Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Shuttle Pharmaceuticals is expected to be smaller as well. At this point, Shuttle Pharmaceuticals has a negative expected return of -1.03%. Please make sure to validate Shuttle Pharmaceuticals' maximum drawdown, rate of daily change, as well as the relationship between the Rate Of Daily Change and relative strength index , to decide if Shuttle Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Shuttle Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Last Split Factor 1:8 | Last Split Date 2024-08-13 |
1 | Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 | 01/07/2025 |
2 | Short Interest in Shuttle Pharmaceuticals Holdings, Inc. Expands By 1,312.5 | 01/13/2025 |
3 | Shuttle Pharmaceuticals Hits Milestone in Patient Enrollment for Phase 2 Clinical Trial | 01/21/2025 |
4 | Shuttle Pharmaceuticals reports FY results | 02/26/2025 |
5 | Shuttle Pharma Announces Pricing of 5.75 Million Underwritten Offering | 03/12/2025 |
6 | Shuttle Pharma Announces Closing of 5.75 Million Underwritten Offering | 03/13/2025 |
Begin Period Cash Flow | 2.6 B |
Shuttle |
Shuttle Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 80.00 in Shuttle Pharmaceuticals on December 25, 2024 and sell it today you would lose (41.00) from holding Shuttle Pharmaceuticals or give up 51.25% of portfolio value over 90 days. Shuttle Pharmaceuticals is currently does not generate positive expected returns and assumes 6.0694% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than Shuttle, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Shuttle Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Shuttle Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Shuttle Pharmaceuticals, and traders can use it to determine the average amount a Shuttle Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1701
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | SHPH |
Estimated Market Risk
6.07 actual daily | 54 54% of assets are less volatile |
Expected Return
-1.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Shuttle Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Shuttle Pharmaceuticals by adding Shuttle Pharmaceuticals to a well-diversified portfolio.
Shuttle Pharmaceuticals Fundamentals Growth
Shuttle Stock prices reflect investors' perceptions of the future prospects and financial health of Shuttle Pharmaceuticals, and Shuttle Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Shuttle Stock performance.
Return On Equity | -3.84 | ||||
Return On Asset | -1.14 | ||||
Current Valuation | 1.89 M | ||||
Shares Outstanding | 6.26 M | ||||
Price To Book | 3.72 X | ||||
EBITDA | (7.7 B) | ||||
Net Income | (9.14 M) | ||||
Cash And Equivalents | 50.44 K | ||||
Total Debt | 1.65 B | ||||
Debt To Equity | 0.09 % | ||||
Current Ratio | 0.03 X | ||||
Book Value Per Share | 0.17 X | ||||
Cash Flow From Operations | (7.33 B) | ||||
Earnings Per Share | (3.30) X | ||||
Market Capitalization | 2.47 M | ||||
Total Asset | 2.51 B | ||||
Retained Earnings | (34.58 B) | ||||
Working Capital | 677.15 K | ||||
About Shuttle Pharmaceuticals Performance
By evaluating Shuttle Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Shuttle Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Shuttle Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Shuttle Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (3.65) | (3.47) | |
Return On Capital Employed | (7.91) | (7.52) | |
Return On Assets | (3.65) | (3.47) | |
Return On Equity | (12.90) | (12.25) |
Things to note about Shuttle Pharmaceuticals performance evaluation
Checking the ongoing alerts about Shuttle Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Shuttle Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Shuttle Pharmaceuticals generated a negative expected return over the last 90 days | |
Shuttle Pharmaceuticals has high historical volatility and very poor performance | |
Shuttle Pharmaceuticals has some characteristics of a very speculative penny stock | |
Shuttle Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
Shuttle Pharmaceuticals currently holds 1.65 B in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Shuttle Pharmaceuticals has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Shuttle Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
Net Loss for the year was (9.14 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Shuttle Pharmaceuticals currently holds about 50.44 K in cash with (7.33 B) of positive cash flow from operations. | |
Roughly 18.0% of Shuttle Pharmaceuticals outstanding shares are owned by corporate insiders | |
Latest headline from globenewswire.com: Shuttle Pharma Announces Closing of 5.75 Million Underwritten Offering |
- Analyzing Shuttle Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Shuttle Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Shuttle Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Shuttle Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Shuttle Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Shuttle Pharmaceuticals' stock. These opinions can provide insight into Shuttle Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Shuttle Stock analysis
When running Shuttle Pharmaceuticals' price analysis, check to measure Shuttle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shuttle Pharmaceuticals is operating at the current time. Most of Shuttle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Shuttle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shuttle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Shuttle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |